LBX2-AS1 in acceleration of glycolysis and cancer angiogenesis via miR-491-5p/MDK signaling axis in colorectal cancer: an experimental study Authors: Juan Wang, Chao Li, Guanghai Wu, Jing Xu Published: 2025 ABSTRACT AbstractBackgroundRecent studies have identified various roles for long non-coding RNAs (lncRNAs) in cancer progression. However, an in-depth understanding of the regulatory mechanisms of lncRNAs in colorectal cancer (CRC) and their diagnostic significance is rather limited.Materials and methodsThe diagnostic value of LBX2 antisense RNA 1 (LBX2-AS1) was assessed using public databases and clinical samples. Cell-counting kit 8 (CCK-8), Colony Formation, transwell, and wound scratch assays were performed to assess CRC cell proliferation and metastasis in vitro. Glucose consumption, lactate production, adenosine triphosphate (ATP), extracellular acidification rate (ECAR), and oxygen composition rate (OCR) were evaluated in CRC cells. A dual luciferase assay was used to verify the target-binding relationship of LBX2-AS1/microRNA (miR)-491-5p/midkine (MDK). BALB/C nude mice were used to establish a subcutaneous xenograft mouse model. The role of the LBX2-AS1/MDK axis in CRC proliferation and angiogenesis was analyzed in vivo.ResultsAs a marker of poor prognosis, LBX2-AS1 was highly expressed in CRC tumor tissues and cells (all p < 0.01). Downregulation of LBX2-AS1 inhibited the proliferation, migration, and invasion of CRC cells (all p < 0.01). Furthermore, the levels of glucose consumption, lactate production, ATP, ECAR, glycolytic-related indicators, and markers of angiogenesis were also inhibited by the downregulation of LBX2-AS2 expression (all p < 0.01). Overexpression of MDK reversed the downregulation of LBX2-AS1 inhibition of these biological activities in CRC cells (all p < 0.01). Downregulation of LBX-AS1 inhibited tumor growth and angiogenesis in vivo (all p < 0.001). Overexpression of MDK reversed the downregulation of LBX2-AS1 inhibition of tumor growth and angiogenesis in vivo (all p < 0.001). Mechanistically, LBX2-AS1 regulated MDK transcription by mediating miR-491-5p.ConclusionThis study demonstrates that LBX2-AS1 promotes CRC angiogenesis and activates the glycolysis via the miR-491-5p/MDK axis. LBX2-AS may serve as a novel diagnostic biomarker and potential therapeutic target for CRC. Introduction Colorectal cancer (CRC) is one of the most common types of cancer in terms of incidence and mortality [1]. More than 1.85 million cases of CRC are diagnosed each year, and 850,000 people die of CRC [2]. There are many treatment strategies for CRC, including surgical resection, chemotherapy, alternative therapies, and chemotherapy combined with monoclonal antibodies [3]. However, despite an expanding range of screening and treatment options, the survival rate of patients with CRC remains low. 30%–35% of patients survive for more than 3 years, and less than 20% survive for 5 years after diagnosis [2]. Therefore, studying the complex signaling pathway, elucidating the underlying mechanism of CRC progression, and identifying CRC therapeutic targets are crucial. It is necessary to induce angiogenesis during tumor growth for development, invasion, and metastasis [4]. Increased secretion of angiogenic factors and downregulation of angiogenic inhibitors can lead to tumor angiogenesis [5]. Endothelial metabolism, including glycolysis, fatty acid oxidation, and glutamine metabolism, drives angiogenesis [6]. Research indicates that aerobic glycolysis is a key feature of CRC metabolism. Tumor cells obtain energy in the form of lactate and other forms during glycolysis [7]. Therefore, the inhibition of tumor neovascularization by targeting the glycolysis pathway is a potential therapeutic strategy. Long non-coding RNAs (lncRNAs) are defined as RNA polymerase II transcripts longer than 200 nucleotides in length that lack a significant protein-coding capacity [8]. It has been demonstrated lncRNAs possess abundant microRNA (miRNA) binding sites and can act as miRNA sponges. Thus, lncRNAs play an essential regulatory role in diseases by interacting with disease-related miRNAs [9]. Recent studies have implicated lncRNAs in cancer occurrence and progression [10]. Accumulating evidence suggests that alterations in lncRNA expression levels are responsible for the carcinogenesis of CRC, which may be useful for CRC diagnosis and treatment [11]. LBX2 antisense RNA 1 (LBX2-AS1) is an emerging non-coding RNA that is highly expressed in various tumors [12]. LBX2-AS1 is significantly associated with the occurrence of gastric cancer [13]. LBX2-AS1 proliferates significantly in thyroid cancer tissues, and LBX2-AS1 is significantly associated with clinical features [14]. Moreover, LBX2-AS1 is associated with CRC development. Li et al. found that downregulation of LBX2-AS1 inhibited cancer cell proliferation [15]. Ma et al. suggested that LBX2-AS1 could regulate CRC progression via the miR-491-5p-S100 calcium-binding protein A11 (S100A11) axis [16]. In addition, Zhao et al. found that LBX2-AS1 promotes CRC progression of CRC via binding to polypyrimidine tract binding protein 1 (PTBP1) [17]. Nevertheless, LBX2-AS1 has been poorly studied in CRC. The potential mechanisms by which LBX2-AS1 affects CRC-related functions and the regulatory networks (upstream components and downstream pathways) behind these functions have not been fully studied. This study examined the role of LBX2-AS1 in CRC. The prognostic and diagnostic values of LBX2-AS1 in CRC were evaluated. Further, we explored the effect of LBX2-AS1 on CRC glycolysis and angiogenesis by regulating Midkine (MDK) in vitro and in vivo. The mechanism through which LBX-AS1 influences MDK transcription was investigated. The study proved the role of LBX2-AS1 and MDK in glycolysis and angiogenesis in CRC. Subjects, materials and methods Bioinformatics analysis Differential expression of LBX2-AS1 and MDK in cancer and normal tissues was evaluated using The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/). The TCGA-related data were processed using the ‘dplyr’ package, visualized using ‘ggplot2’ package [18,19]. Clinical data for CRC patients were sourced from the TCGA database. The R package ‘survminer’ was utilized to construct survival curves for overall survival (OS) and disease-specific survival (DSS) [20]. The protein expression levels of MDK in cancer and normal tissues were also illustrated using The University of ALabama at Birmingham CANcer data analysis portal (UALCAN) database (http://ualcan.path.uab.edu) [21]. Sample collection The Ethics Committee of Tianjin Union Medical Center agreed to enroll the patients (Approval number: 2024-B09). All 20 patients signed informed consent forms, and their tissues were collected. The inclusion criterion was the absence of preoperative chemoradiation or chemotherapy. The clinical data were complete, and the postoperative pathological diagnoses were confirmed by two pathologists. The inclusion of patients with CRC was consistent with the comprehensive pathological diagnosis of CRC. The clinical stages of the patients were recorded, and tumor and para-cancer samples were collected. The 20 CRC patients, comprising 10 men and 10 women, were aged between 35 and 61 years, with a mean age of 45.8 ± 7.2 years. Among the patients, 12 had a tumor diameter of 4 cm or less, while 8 had a tumor diameter greater than 4 cm. In total, 20 patients were diagnosed with colon cancer. According to the Dukes Modified Astler-Coller (MAC) staging criteria, 9 patients had stage A,7 patients had stage B, and 4 patients had stage C [22]. Cell line and cell culture Human colon epithelial cells (HCoEpiC), five colon cancer cell lines (SW620, HT-29, DLD-1, HCT116, and LoVo), and 293 T cells were purchased from ATCC (Manassas, VA, USA). HCoEpiCs, 293 T, and CRC cells were cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (HyClone) and 1% penicillin-streptomycin. All cells were cultured at 37 °C with 5% CO2. Cell transfection Small hairpin (sh)-LBX2-AS1, microRNA(miR)-491-5p-inhibitor, and MDK-silenced/overex expression plasmid vectors were constructed by RiboBio (Guangzhou, China). shRNA LBX2-AS1, shRNA MDK, and LBX2-AS1 + MDK shRNA were generated. Stable expression plasmids, inhibitors, and shRNAs were transfected into cells via LipoFectamine-2000 (Invitrogen, Carlsbad, CA, USA). Quantitative real-time polymerase chain reaction (qRT-PCR) Total RNA was extracted using the via TrIzol Reagent (Vazyme, Nanjing, China). The concentration and purity of total RNA were determined at an optical density (OD) of 260 nm, and the OD260/OD280 ratio was compared. cDNA was constructed using Hifair® III 1st Strand cDNA Synthesis SuperMix (Yeasen Biotechnology, Shanghai, China). qRT-PCR was conducted using the Hieff UNICON® Universal Blue qPCR SYBR Green Master Mix (Yeasen Biotechnology). The relative RNA expression levels were calculated using the 2−ΔΔCt method. The primers: LBX2-AS1: Forward (F): CAATTCGCAGGAAGGGGAGT, Reverse (R): ACAAACTGTATGGAGGCGCA, miR-491-5p: F: GGAGTGGGGAACCCTTCC, R: GTGCAGGGTCCGAGGT, MDK: F: GCTACAATGCTCAGTGCCAGGA, R: CTTGGCGTCTAGTCCTTTCCCT, VEGFA: F: TTGCCTTGCTGCTCTACCTCCA, R: GATGGCAGTAGCTGCGCTGATA, PFKFB3: F: GGCAGGAGAATGTGCTGGTCAT, R: CATAAGCGACAGGCGTCAGTTTC, GLUT1: F: TTGCAGGCTTCTCCAACTGGAC, R: CAGAACCAGGAGCACAGTGAAG, HK2: F: GAGTTTGACCTGGATGTGGTTGC, R: CCTCCATGTAGCAGGCATTGCT, PGK1: F: CCGCTTTCATGTGGAGGAAGAAG, R: CTCTGTGAGCAGTGCCAAAAGC, GAPDH:F: CCACATCGCTCAGACACCAT, R: TGACAAGCTTCCCGTTCTCA, U6: F: CAGCTGTGCGTGTGACAGC, R: CTCAACTGGTGTCGTGGAGTC. Cell viability assay Cell proliferation was measured using the Cell Counting Kit 8 (CCK-8) assay as previously described [23]. Cells were inoculated into four 96-well plates (5 × 103 cells/well). A cell suspension (100 µL) was prepared. The culture plates were incubated for 24 h. Next, 10 µL of the different substance concentrations were added to the culture plate. The plates were incubated for an appropriate period. Briefly, The CCK-8 reagent (10 µL) from Yeasen Biotechnology (Shanghai, China) was added. the CCK-8 reagent (10 µL) (Yeasen Biotechnology, Shanghai, China) was added. Absorbance at 450 nm was measured using a spectrophotometer (Thermo Fisher Scientific). Colony formation CRC cells were seeded at a density of 200 cells/mL in 6-well plates, with each well receiving 500 μL, and incubated at 37 °C with 5% CO2. After two weeks of culture, the culture was terminated when visible clones were frequently observed. The supernatant was removed, and the sample was rinsed twice with phosphate-buffered saline (PBS). Cells were fixed using 4% paraformaldehyde (Boster Biotechnology, Wuhan, China) in a 5 mL volume. Crystal violet dye (Merck Drugs & Biotechnology, NJ, USA) was applied, left to stain for 10–20 min, then gently rinsed with running water and dried. Clones on the plates were microscopically counted [24]. Transwell assay Matrigel matrix (Beyotime Biotechnology, Shanghai, China) adhesive was diluted 1:8 and coated with the upper compartment of the bottom membrane of the 24-well transwell compartment. After air drying for 3 h, the residual liquid was removed, a serum-free culture medium containing 50 μL Bovine Serum Albumin (BSA) (Servicebio, Wuhan, China) was added, and the culture was hydrated at 37 °C for 30 min. A 200 μL cell suspension at 5 × 105 cells/mL was placed in the Transwell’s upper chamber, while 600 μL of culture medium with 10% FBS (Servicebio) was added to the lower chamber. The culture plates were incubated in a CO2 incubator at 37 °C for 24 h. The cells were fixed in a 24-well plate with 4% paraformaldehyde (Boster Biotechnology) for 20 min and stained with a crystal violet (Merck Drugs & Biotechnology) solution for 15 min. Images were captured using an inverted microscope. Cell wound scratch assay A marker is used to draw straight lines behind the 6-hole board. Approximately 5 × 105 cells were uniformly inoculated into each well and cultured in a 5% CO2 incubator at 37 °C for 12 h. Furthermore, we drew a straight line through the hole with a sterilized 20 µL tip. After completion, the cells were washed three times with sterile PBS to clean off the scratched cells so that the remaining gap was visible to the naked eye, and then the fresh medium was replaced. The cells were maintained at 37 °C in a 5% CO2 incubator. After 24 h, the cells were extracted, observed microscopically, and photographed. Nucleocytoplasmic separation HCT116 cells were cultured in 12-well plates. PBS was used for cell cleansing, followed by cell scraping, cell collection via centrifugation, removal of the supernatant, and retention of the cell precipitate. A nuclear and cytoplasmic protein extraction kit (Norgen Biotek Corp., Thorold, Canada) was used to isolate the nuclear and cytoplasmic proteins. The expression of LBX2-AS1 in the nucleus and cytoplasm was detected by qRT-PCR. Fluorescence in situ hybridization (FISH) DLD-1 and HCT116 cells were cultured in a confocal dish for 24 h, then fixed, pre-hybridized, and hybridized overnight with lncRNA LBX2-AS1 and MDK oligodeoxynucleotide probes (GenePharma, Shanghai, China) in a hybridization buffer. A fluorescent FISH kit (Thermo Fisher Scientific, MA, USA) was used to detect probe signals, while 4′,6-diamidino-2-phenylindole stained cell nuclei. Images were examined using a confocal microscope. Immunohistochemical assay The tumor sections were soaked and cleaned in dewaxing solution, anhydrous ethanol, alcohol, and distilled water. Tissue sections were placed in a microwave oven repair box filled with ethylenediaminetetraacetic acid (pH 8.0) for antigen retrieval. The sections were treated with 3% hydrogen peroxide for 25 min, followed by three PBS rinses. The tissue was coated evenly with a 3% BSA solution within a chemical ring and sealed for 30 min at 20 °C. The sealant was then shaken gently and an antibody (MDK and CD31, 1:500, Proteintech, Wuhan, China) was added to the slice. After incubation at 4 °C overnight, wash with PBS thrice. After the slices were slightly dried, the tissue was incubated with a secondary antibody (horseradish peroxidase (HRP)-labeled Goat Anti-Rabbit Immunoglobulin (IgG), 1:500, Beyotime Biotechnology, Shanghai, China) specific to the primary antibody species for 50 min, followed by three washes with PBS. Following partial drying of the sections, freshly prepared diaminobenzidine color-developing solution (Beyotime Biotechnology, Shanghai, China) was applied to the circle. Color development was carefully monitored under a microscope, with a positive color appearing brown and yellow. The reaction was stopped by rinsing sections with tap water. Hematoxylin redye (Beyotime Biotechnology, Shanghai, China) was used for approximately 3 min, rinsed with tap water, briefly treated with hematoxylin differentiation solution, rinsed with tap water, stained with hematoxylin blue solution, and rinsed with running water. Subsequently, the tissue slices were dehydrated and sealed. Microscopic inspection, image capture, and subsequent analyses were performed. Patients with CRC were classified into pathological stages A, B, and C using the Duke staging method. Microvascular density (MVD) counting standards: According to the Weidner counting method, the microvascular dense area was determined under a low-power microscope, the number of microvessels in five different fields was counted under a high-power microscope, and the average value was the MVD (unit: one/200-fold field). Endothelial cells were counted according to independent blood vessels, not according to vascular lumen formation or the presence of red blood cells in the lumen. Patients were excluded if they had a large lumen, a thick muscle layer, or more than eight red blood cells in the lumen. Western blot analysis Protein extraction from cells and tissues was performed using a radioimmunoprecipitation assay buffer (Solarbio Science & Technology, Beijing, China). The lysate obtained was centrifuged at 4 °C and 12,000 rpm for 30 min and then quantified using a BCA kit (Solarbio Science & Technology, Beijing, China). Proteins were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Epizymr Biotechnology, Shanghai, China) and then transferred onto a polyvinylidene fluoride (PVDF) membrane (Merck Millipore, New Jersey, USA). The membranes were blocked with PBS (Beyotime Biotechnology, Shanghai, China) and Tween-20 (PBST) buffer (Beyotime Biotechnology) in 5% skim milk and incubated at 4 °C overnight with primary antibodies (MDK, VEGFA, PFKB3, GLUT1, HK2, PGK1, GAPDH, 1:1000, Proteintech, Wuhan, China). The membrane was washed and incubated with secondary antibodies (Goat Anti-rabbit HRP and Goat Anti-mouse HRP, 1:5000; Proteintech, Wuhan, China). Results were obtained using enhanced chemiluminescence (ECL; Proteintech). Metabolic assays Glucose-6-phosphate assay kit (Beyotime Biotechnology), lactate dehydrogenase assay kit (Beyotime Biotechnology), and CellTiter-Glo 2.0 assay kit (Beyotime Biotechnology) were used to detect intracellular glucose consumption, lactate production, and adenosine triphosphate (ATP) production, respectively. The extracellular acidification rate (ECAR) (Bestbio, Jiangsu, China) and oxygen consumption rate (OCR) (Bestbio) were measured using a hippocampal XF96 extracellular flux analyzer (Agilent, Calif, USA). Transfected cells (2 × 104/well) were incubated overnight in eight 96-well plates. Glucose, oligomycin (oxidative phosphorylation inhibitor), and 2-DG (glycolysis inhibitor) were added to the wells to measure the ECAR. OCR was determined by adding hypomycin, p-trifluoromethoxycarbonyl cyanide phenylhydrazone, and rotenone/antimycin A to the pores. Seahorse XF-96 software was used to analyze the data. Dual luciferase assay To explore the relationship between miR-491-5p and LBX2-AS1, CRCs treated with miR-491-5p-inhibitor or NC-inhibitor were cultured in 96-well plates and transfected with either wild-type or mutant LBX2-AS1 using Lipofectamine 2000 (Invitrogen). CRCs transfected with miR-491-5p-inhibitor and NC-inhibitor were further transfected with either MDK WT- or MUT-type plasmids to explore the interaction between MDK and miR-491-5p. Luciferase activity was quantified using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) following a 48 h incubation [25]. Xenograft mice models establishment An experimental model of xenotransplantation was established using 18–20 g, 6-week-old male BALB/C nude mice (Vital River Laboratory Animal Technology, Beijing, China). The animal trial was approved by the Ethics Committee of the Tianjin Union Medical Center (Approval number: TUMC2024-029). The experiment was divided into control, sh-LBX2-AS1, sh-MDK, and sh-LBX2-AS1 + MDK groups, with six mice in each group (Total number = 24). DLD-1 cells (1 × 107; 200 μL) were inoculated into the middle posterior part of the axilla. Tumor growth was tracked regularly, and tumor size was assessed weekly. After 35 days, all mice were euthanized by intraperitoneal injection with 1% pentobarbital sodium (100 mg/kg, Sigma–Aldrich, St. Louis, MO, USA) for 15 min, in accordance with euthanasia of Animals guidelines of American Veterinary Medical Association (AVMA) [26,27]. The tumor tissue was dissected and photographed, the volume and weight of the tumor were recorded, and the tumor tissue was collected for analysis. All animal experiments followed the ARRIVE guidelines. Statistical analysis All in vitro results were replicated in triplicates. All the in vivo results were replicated in six experiments. Experimental data are presented as mean ± standard deviation (SD). Data analysis was conducted using SPSS software (Version 26.0; SPSS, Inc., Chicago, IL, USA). The Shapiro–Wilk test was initially employed to assess normal distribution, and the Levene test was subsequently used to evaluate variance homogeneity. Group differences were assessed using two-tailed unpaired Student’s t-tests or one-way ANOVA followed by Tukey’s post hoc test.A non-parametric Kruskal-Wallis test was applied when the data did not follow a normal distribution. Cox regression analyses, both univariate and multivariate, were conducted to assess the relationship between LBX2-AS1 expression and patient prognosis. p < 0.05 indicate statistical significance. Results LBX2-AS1 was upregulated and associated with malignant progression in patients with CRC To study the relationship between LBX2-AS1 and the occurrence of CRC, we first investigated the differential levels of LBX2-AS1 using TCGA database. In the tumor group, LBX2-AS1 expression was significantly increased compared to that in the normal tissues (p < 0.001, Figure 1(A)). Patients diagnosed with advanced stage III and IV CRC exhibited elevated LBX2-AS1 expression levels (Figure 1(B)). This expression trend was also confirmed in 20 patients with CRC (p < 0.01, Figure 1(C)). Patients exhibiting elevated LBX2-AS1 levels generally experienced reduced OS (HR = 2.17, p < 0.001) and DSS rates (HR = 2.11, p < 0.01) (Figure 1(D and E)). Analysis of TCGA database data indicated that LBX2-AS1 expression is significant in CRC patients and serves as an independent predictor of CRC (all p < 0.05, Figure 1(F and G)). The findings demonstrate that LBX2-AS1 significantly influences CRC cell proliferation, migration, and invasion. The Expression level of LBX2-AS1 was higher in CRC tissues. A: The mRNA expression of LBX2-AS1 in CRC and normal tissues in TCGA database. B: The mRNA expression of LBX2-AS1 in different stages of CRC tissues in the TCGA database. C: The mRNA expression of LBX2-AS1 tumor and normal tissues in 20 patients with CRC (n = 20 for paracancer tissues and n = 20 for CRC). D: Relationship between high and low expression of LBX2-AS1 and overall survival in the TCGA database. E: Relationship between high and low expression of LBX2-AS1 and disease special survival in TCGA database. F: LBX2-AS1 expression at different stages of CRC was analyzed using univariate analysis. G: LBX2-AS1 expression at different stages of CRC was analyzed by multiple analyses. All data are represented as the mean ± SD. **p < 0.01, ***p < 0.001. LBX2-AS1, LBX2 antisense RNA 1; CRC: colorectal cancer; TCGA: The cancer Genome Atlas; SD: standard deviation; HR: hazard ratio. Downregulation of LBX2-AS1 expression inhibited the proliferation, migration, and invasion of CRC After identifying the relationship between high expression of LBX2-AS1 and the occurrence of CRC, we explored the effects of LBX2-AS1 on the proliferation, migration, and invasion of CRC cells in vitro. Compared to HcoEpiC cells, LBX2-AS1 was upregulated in CRC cells, among which DLD-1 and HCT116 cells had the highest LBX2-AS1 expression, and were selected for subsequent experiments (all p < 0.001, Figure 2(A)). We then constructed DLD-1 and HCT116 cell lines with low LBX2-AS1 expression (all p < 0.001, Figure 2(B)). In HCT116 cells, LBX2-AS1 was highly expressed in the cytoplasm (Figure 2(C)). The results of CCK-8 and colony formation assays proved that inhibition of LBX2-AS1 expression significantly downregulated the proliferative activity of DLD-1 and HCT116 cells (all p < 0.001, Figure 2(D and E)). Inhibition of LBX2-AS1 expression also significantly repressed the migration and invasion of DLD-1 and HCT116 cells (all p < 0.001, Figure 2(F, G and H)). These results prove that LBX2-AS1 plays a significant role in regulating the proliferation, migration, and invasion of CRC cells. Downregulation of LBX2-AS1 expression inhibited CRC cell proliferation, migration, and invasion. A: the mRNA expression of LBX2-AS1 in HCoEpiC and five colon cancer cell lines (n = 3). B: the transcription levels of LBX2-AS1 in DLD-1 and HCT116 cells from different treatment groups were detected using qRT-PCR (n = 3). C: expression of LBX2-AS1 in the nucleus and cytoplasm (n = 3). D: the effect of sh-LBX2-AS1 on the proliferation of CRC cells was measured by CCK-8 assay (n = 3). E: the effect of sh-LBX2-AS1 on the proliferation of CRC cells was measured by colony formation assay (n = 3). F and G: the effect of sh-LBX2-AS1 on the migration and invasion of CRC cells was measured by transwell assay (n = 3). H: the effect of sh-LBX2-AS1 on CRC cell migration was measured by cell wound scratch assay (n = 3). All data are represented as the mean ± SD. ***p < 0.001. LBX2-AS1, LBX2 antisense RNA 1; CRC: colorectal cancer; HCoEpiC: human colon epithelial cells; qRT-PCR: quantitative real-time polymerase chain reaction; CCK-8: cell Counting kit 8; SD: standard deviation; sh-NC: small hairpin RNA-negative control; GAPDH: glyceraldehyde-3-phosphate dehydrogenase. MDK expression was upregulated and associated with malignant progression in patients with CRC In CRC, MDK may play a role in promoting CRC [28]. MDK promotes tumor growth by inducing angiogenesis and is a potent pro-angiogenic factor [29]. Hence, following elucidation of the impact of LBX2-AS1 on CRC, we investigated the association between MDK and CRC. We analyzed the differences in mRNA and protein expression of MDK using the TCGA and UALCAN databases, respectively. MDK was significantly upregulated in the tumor group (all p < 0.001; Figure 3(A and B)). This expression trend was also confirmed in 20 patients with CRC (p < 0.001, Figure 3(C)). There was a correlation between LBX2-AS1 and MDK expression in patients with CRC (R2 = 0.3866) (Figure 3(D)). Immunohistochemistry results demonstrated that MDK was upregulated in the tumors and later clinical stages (Figure 3(E)). These findings suggest that MDK expression is increased in colorectal cancer and is associated with the progression of malignancy. MDK expression level was higher in CRC tissues. A: The mRNA expression of MDK in CRC and normal tissues in TCGA database. B: The protein expression of MDK in CRC and normal tissues in the UALCAN database. C: MDK mRNA expression in 20 patients with CRC and the control group (n = 20 for paracancer tissues and n = 20 for CRC). D: correlation between LBX2-AS1 and MDK expression in CRC. E: MDK expression at different stages of CRC was observed by immunohistochemistry (n = 20 for paracancer tissues and n = 20 for CRC). All data are represented as the mean ± SD. ***p < 0.001. CRC: colorectal cancer; MDK: midkine; TCGA: The cancer Genome Atlas; UALCAN: University of ALabama at birmingham CANcer data analysis portal; SD: standard deviation. MDK expression in CRC was positively correlated with LBX2-AS1 In addition, we investigated the correlation between LBX2-AS1 and MDK expression. Double staining showed that LBX2-AS1 and MDK co-localized in DLD-1 and HCT116 cells (Figure 4(A)). MDK expression was lower in the sh-LBX2-AS1 group than in the sh-NC group (all p < 0.001; Figure 4(B and C)). After silencing MDK, MDK expression in DLD-1 and HCT116 cells decreased (all p < 0.001; Figure 4(D and E)). These results indicate that LBX2-AS1 can regulate MDK expression in CRC cells, and that MDK expression is positively correlated with LBX2-AS1 expression. LBX2-AS1 And MDK expressions were positively correlated. A: LBX2-AS1 and MDK are co-localized in CRC cells (n = 3). B and C: The transcription (B) and protein (C) levels of MDK in DLD-1 and HCT116 cells of different treatment groups were detected by qRT-PCR and Western blot analysis (n = 3). D: The MDK expression in DLD-1 and HCT116 cells after MDK inhibition (n = 3). E: The protein levels of MDK in DLD-1 and HCT116 cells from different treatment groups were detected by Western blot analysis. All data are represented as the mean ± SD. ***p < 0.001. LBX2-AS1, LBX2 antisense RNA 1; MDK: midkine; CRC: colorectal cancer; qRT-PCR: quantitative real-time polymerase chain reaction; SD: standard deviation; DAPI: 4,6-Diamino-2-phenylindole. Downregulation of LBX2-AS1 expression inhibited the proliferation, migration, and invasion of CRC via MDK To explore the influence of the LBX2-AS1 − MDK axis on CRC biology, we added the sh-LBX2-AS1 + MDK group. After upregulating MDK, MDK in DLD-1 and HCT116 cells increased (Supplementary Fig. S1). The growth potential of CRC cells in each group was assessed using the CCK-8 and colony formation assays. Cell proliferation was notably decreased in the sh-LBX2-AS and sh-MDK groups, while CRC cell proliferation activity significantly increased following MDK addition (all p < 0.001, Figure 5(A and B)). The migration and invasion capabilities of CRC cells were notably reduced in the sh-LBX2-AS and sh-MDK groups, with a significant reversal observed following MDK supplementation (all p < 0.001, Figure 5(C and D); Supplementary Fig. S2). Downregulation of LBX2-AS1 expression inhibited proliferation, migration, and invasion of CRC cells via MDK. A: The effect of sh-LBX2-AS1, sh-MDK, and sh-LBX2-AS1 + MDK on the proliferation of CRC cells was measured by CCK-8 assay (n = 3). B: The effect of sh-LBX2-AS1, sh-MDK, and sh-LBX2-AS1 + MDK on the proliferation of CRC cells was measured by colony formation assay (n = 3). C and D: The effect of sh-LBX2-AS1, sh-MDK, and sh-LBX2-AS1 + MDK on the migration (C) and invasion (D) of CRC cells was measured by transwell assay (n = 3). All data are represented as the mean ± SD. **p < 0.01, ***p < 0.001. LBX2-AS1: LBX2 antisense RNA 1; CRC: colorectal cancer; MDK: midkine; sh: small hairpin; CCK-8: cell Counting kit 8; SD: standard deviation. Downregulating the expression of the LBX2-AS1/MDK axis inhibited CRC glycolysis and angiogenesis Furthermore, we explored the regulation of CRC glycolysis and angiogenesis by the LBX2-AS1/MDK axis. VEGFA and glycolysis-related factor (PFKB3, GLUT1, HK2, and PGK1) expression in CRC cells was significantly decreased upon LBX2-AS1 and MDK downregulation, but was restored upon MDK addition (all p < 0.001, Figure 6(A and B)). Moreover, glucose consumption, lactate production, and ATP levels were reduced in the sh-LBX2-AS1 and sh-MDK groups and were reversed after the addition of MDK (all p < 0.001, Figure 6(C, D and E)). LBX2-AS1 and MDK inhibition downregulated ECAR levels, which were reversed after the addition of MDK (Supplementary Fig. S3A). LBX2-AS1 and MDK inhibition upregulated OCR levels, which were reversed after the addition of MDK (Supplementary Fig. S3B). These results suggest that downregulation of the LBX2-AS1/MDK axis inhibits CRC glycolysis and can be reversed by adding MDK. Downregulating the LBX2-AS1/MDK axis expression inhibited CRC glycolysis and angiogenesis. A: The transcription levels of VEGFA, PFKB3, GLUT1, HK2, and PGK1 in DLD-1 and HCT116 cells from different treatment groups were detected by qRT-PCR (n = 3). B: The protein levels of VEGFA, PFKB3, GLUT1, HK2, and PGK1 in DLD-1 and HCT116 cells from different treatment groups were detected by Western blot analysis (n = 3). C: Glucose consumption levels in DLD-1 and HCT116 cells (n = 3). D: Lactate production levels in DLD-1 and HCT116 cells. E: ATP levels in DLD-1 and HCT116 cells (n = 3). All data are represented as the mean ± SD. ***p < 0.001. LBX2-AS1: LBX2 antisense RNA 1; MDK: midkine; CRC: colorectal cancer; VEGFA: vascular endothelial growth factor A; PFKB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; GLUT1: Glucose transporter 1; HK2: hexokinase2; PGK1: phosphoglycerate kinase 1; qRT-PCR: quantitative real-time polymerase chain reaction; ATP: adenosine triphosphate; SD: standard deviation. Downregulating the LBX2-AS1/MDK axis inhibited CRC tumor growth In in vivo experiments, silencing LBX2-AS1 and MDK led to a notable reduction in tumor tissue volume and weight in mice. After MDK was added, the inhibition was reversed and CRC tumors grew rapidly (all p < 0.001, Figure 7(A, B and C)). Immunohistochemical examination of tumor tissues showed that the MVD of tumor tissue in the sh-LBX2-AS1 and sh-MDK groups was significantly reduced. Compared to the sh-LBX2-AS1 and sh-MDK groups, MVD increased in the sh-LBX2-AS1 + MDK group (all p < 0.001, Figure 7(D)). These results prove that suppressing the LBX2-AS1/MDK axis has the potential to impede the growth of CRC tumors. Downregulating the LBX2-AS1/MDK axis inhibited the growth of CRC tumors. A: Tumor appearance (n = 6). B: Tumor volume at 0, 7, 14, 21, 28 and 35 d (n = 6). C: Tumor weight at 35 d (n = 6). D: Tumor MVD was observed using immunohistochemistry (n = 6). All data are represented as the mean ± SD. ***p < 0.001. LBX2-AS1: LBX2 antisense RNA 1; MDK: midkine; CRC: colorectal cancer; MVD: microvascular density; SD: standard deviation; sh: small hairpin. LBX2-AS1 serves as a sponge of miR-491-5p to regulate the transcription level of MDK Previous studies have shown that LBX2-AS1 is upregulated in the cytoplasm. Therefore, we speculated that the transcriptional regulation of MDK by LBX2-AS1 is mediated by miRNAs. Using the ENCORI database, we identified 11 miRNAs that bound to both LBX2-AS1 and MDK (Figure 8(A)). Among them, miR-491-5p has been shown to be effective in cancer inhibition in CRC [30]. Previous studies have found that LBX2-AS1 regulates the proliferation and migration of CRC by mediating miR-491-5p [16]. Therefore, miR-491-5p was chosen as the target miRNA for subsequent studies. Using the starBase and miRDB databases, we predicted the binding sites of miR-491-5p to LBX2-AS1 and MDK, respectively (Figure 8(B)). CRC cell lines with reduced miR-491-5p expression were successfully established (all p < 0.001, Figure 8(C)). The dual-luciferase assay verified the binding relationship between miR-491-5p and LBX2-AS1 and MDK (Figure 8(D and E)). Furthermore, downregulating the expression of LBX2-AS1 inhibited the expression of miR-491-5p in CRC (all p < 0.001, Figure 8(F)). Downregulating miR-491-5p levels in cells reversed the inhibitory effect of sh-LBX2-AS1 on MDK expression (Figure 8(G)). These findings demonstrate that LBX2-AS1 regulates MDK transcription by mediating miR-491-5p expression. LBX2-AS1 Serves as a sponge of miR-491-5p to regulate transcription level of MDK. A: ENCORI database was used to predict miRNAs bind to LBX2-AS1 and MDK. B: starBase and miRDB databases were used to predict the bind sites. C: The transcription level of miR-491-5p in DLD-1 and HCT116 cells after downgulation of miR-491-5p (n = 3). D: The binding relationship between miR-491-5p and LBX2-AS1 was verified by dual luciferase assay (n = 3). E: The binding relationship between miR-491-5p and MDK was verified by dual luciferase assay (n = 3). F: The transcription levels of miR-491-5p in DLD-1 and HCT116 cells (n = 3). G: The protein levels of MDK in DLD-1 and HCT116 cells (n = 3). All data are represented as the mean ± SD. ***p < 0.001. LBX2-AS1: LBX2 antisense RNA 1; MDK: midkine; ENCORI: the encyclopedia of RNA interactomes; SD: standard deviation; WT: wild; MUT: mutant; NC: negative control. Discussion CRC is among the most common fatal cancers, and CRC is increasing globally every year. CRC has a heterogeneous etiology and complex pathogenesis [31]. Therefore, timely detection and effective precision are essential for successful treatment and improved patient survival. lncRNAs are newly discovered functional non-coding RNAs that regulate cancer development through multiple mechanisms [32]. This study explored the regulatory role and mechanism of LBX2-AS1 in glycolysis and angiogenesis in CRC. The long non-coding RNA LBX2-AS1, originating from the intron of chromosome 2p13.1, has been identified as a contributor to the progression of multiple cancer types [16]. LBX2-AS1 enhances tumor cell growth, survival, migration, invasion, and formation in ovarian cancer by inhibiting miR-455-5p and miR-491-5p [33]. The positive feedback loop involving LBX2-AS1/miR-219a-2-3p/FUS/LBX2 in gastric cancer enhances tumor cell proliferation and apoptosis, presenting a novel therapeutic target for patients with gastric cancer [13]. Moreover, LBX2-AS1 was upregulated in thyroid cancer and positively correlated with the progression of disease grade and stage [14]. In CRC, LBX2-AS1 promotes proliferation and invasion of cancer cells by regulating the miR-491-5p/S100A11 axis [16]. Moreover, some researchers have shown that LBX2-AS1 is a poor prognostic factor for colon cancer and can regulate colon cancer progression [34]. In this study, we confirmed through the TCGA database and 20 patients with CRC that LBX2-AS1 expression increased with an increase in the clinical stage. Furthermore, LBX2-AS1 promotes CRC cell proliferation, migration, and invasion in vitro. These findings and outcomes suggest a positive association between the carcinogenic impact of LBX2-AS1 and the progression of malignant CRC. MDK is a heparin-binding growth factor, and Kadomatsu et al. first reported the expression of this gene in retinoic acid-induced mouse embryonic tumor cells [35]. MDK, a cytokine and growth factor with intricate biological functions, plays a significant role in the initiation, progression, infiltration, spread, and other biological activities of numerous tumors, including CRC [36–38]. Ye et al. discovered increased MDK expression in three patients diagnosed with adenomas exhibiting moderate or severe atypical hyperplasia, indicating that elevated MDK may act as a carcinogenic factor in the early stages of CRC [39]. MDK is a clinically significant CRC biomarker associated with poor survival [40]. MDK also has angiogenic effects, and animal experiments have confirmed that MDK increases tumor MVD and promotes endothelial cell proliferation [41]. Because MDK is a soluble secreted protein, its overexpression in tissues increases its blood expression, and the blood test population is highly compliant, simple, safe, and economical. In the present study, MDK was upregulated in CRC and promoted CRC cell proliferation, migration, and invasion. High MDK expression promotes glycolysis in CRC and promotes tumor growth. After MDK expression is downregulated, the proliferation, migration, invasion, glycolysis, and tumor growth of CRC cells are also downregulated. Our study also found that LBX2-AS1 regulated MDK transcription by mediating miR-491-5p expression. After LBX2-AS1 downregulation, MDK expression was downregulated, and LBX2-AS1 and MDK expression were co-localized in the cells. These reports and results further suggest that LBX2-AS1 can promote the malignant progression of CRC via the miR-491-5p/MDK axis. The metabolism of endothelial cells, encompassing glycolysis, fatty acid oxidation, and amino acid metabolism, is crucial for vascular development and structural formation [42–44]. Among them, abnormal glucose metabolism is most closely related to angiogenesis, and studies have shown that endothelial cells use anaerobic glycolysis for energy metabolism up to 80%, even at high oxygen concentrations. Glycolysis can provide energy for angiogenesis, and its products can promote angiogenesis [45]. Owing to the preference of endothelial cells for glycolysis, endothelial energy metabolism and angiogenesis have gradually become new targets for tumor therapy. Lu et al. discovered that Mex3 homolog A (MEX3A) drives angiogenesis in CRC by promoting glycolysis. They also found that inhibiting glycolysis with 2-DG counteracted the pro-angiogenic effects of MEX3A on CRC cell proliferation and glycolysis [46]. SRY-related HMG-box 2 (SOX2) promotes angiogenesis by promoting glycolysis through the lncRNA AC005392.2-GLUT1 axis in CRC, laying the foundation for developing new anti-angiogenesis drugs or novel drug combination targets [47]. Therefore, this study explored another pathway of MDK’s role in promoting angiogenesis and energy metabolism disorders that promote tumor angiogenesis. This study showed that the inhibition of the LBX2-AS1/MDK axis could inhibit glycolysis in CRC cells. The results of in vivo experiments indicated that silencing the LBX2-AS1/MDK axis could inhibit tumor growth and angiogenesis in mice. These reports and results suggest that the LBX2-AS1/MDK axis promotes CRC tumor proliferation, metastasis, and angiogenesis by mediating the glycolytic pathway. However, this study had some limitations. First, LBX2-AS1 may regulate glycolytic activity via various pathways and factors. This study focused on only one signaling axis, miR-491-6p/MDK, and further studies are needed to discover other regulatory pathways of LBX2-AS1. Moreover, mouse tumor models were not used to demonstrate the influence of LBX2-AS1 on glycolysis in this study. Further experiments are required to confirm this hypothesis. Conclusions LBX2-AS1 correlates with the advancement of cancer and enhances the proliferation, migration, and invasion of CRC cells. The LBX2-AS1/miR-491-5p/MDK axis mediates the proliferation, metastasis, and angiogenesis of CRC cells by regulating glycolysis. These findings provide a new direction for the exploration of the molecular mechanisms of tumor neovascularization in CRC, and a new potential target for treating CRC. This promising finding justifies further research in CRC and other cancers where LBX2-AS1 plays a significant functional role. Supplementary Material Supplemental Material Supplemental Material Supplemental Material Supplemental Material